Sotera Health (NASDAQ:SHC) Earns Neutral Rating from Analysts at Piper Sandler

Piper Sandler began coverage on shares of Sotera Health (NASDAQ:SHC) in a research note published on Tuesday, MarketBeat reports. The firm issued a neutral rating and a $13.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. TheStreet upgraded shares of Sotera Health from a d rating to a c- rating in a report on Tuesday, February 27th. Jefferies Financial Group upgraded shares of Sotera Health from a hold rating to a buy rating and upped their price target for the company from $15.00 to $15.50 in a report on Monday, March 25th. Royal Bank of Canada reissued an outperform rating and issued a $20.00 price objective on shares of Sotera Health in a research report on Monday, March 4th. Barclays cut their price objective on shares of Sotera Health from $19.00 to $14.00 and set an overweight rating on the stock in a research report on Wednesday, April 10th. Finally, KeyCorp initiated coverage on shares of Sotera Health in a research report on Tuesday, February 6th. They issued a sector weight rating on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $16.92.

Sotera Health Stock Performance

Shares of SHC stock opened at $11.19 on Tuesday. The company has a market capitalization of $3.17 billion, a P/E ratio of 58.90 and a beta of 2.08. Sotera Health has a 52 week low of $10.71 and a 52 week high of $19.40. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.86 and a current ratio of 3.20. The company’s 50 day moving average price is $11.49 and its two-hundred day moving average price is $13.84.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.01). The company had revenue of $248.18 million during the quarter, compared to analyst estimates of $254.73 million. Sotera Health had a net margin of 5.09% and a return on equity of 48.47%. On average, analysts expect that Sotera Health will post 0.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Director Pincus & Co. Warburg sold 16,594,363 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the sale, the director now directly owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sotera Health news, insider Michael P. Rutz sold 83,109 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.31, for a total value of $1,189,289.79. Following the transaction, the insider now directly owns 544,409 shares in the company, valued at $7,790,492.79. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Pincus & Co. Warburg sold 16,594,363 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the completion of the transaction, the director now owns 88,822,952 shares in the company, valued at $1,271,056,443.12. The disclosure for this sale can be found here. Insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

Institutional investors and hedge funds have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale acquired a new position in shares of Sotera Health in the third quarter valued at $58,000. Quest Partners LLC acquired a new position in shares of Sotera Health in the fourth quarter valued at $139,000. Sandia Investment Management LP acquired a new position in shares of Sotera Health in the first quarter valued at about $120,000. Securian Asset Management Inc. grew its stake in shares of Sotera Health by 23.0% in the first quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock valued at $122,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Allegheny Financial Group LTD acquired a new position in shares of Sotera Health in the fourth quarter valued at about $177,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.